Hansa Biopharma: increase in number of shares and votes

Rhea-AI Summary

Hansa Biopharma has increased its registered share capital and the number of shares and votes. The company issued 2,305,260 new ordinary shares, raising the number of votes by the same amount and increasing the share capital by SEK 2,305,260.

Additionally, all 2,362,445 issued class C shares were converted into ordinary shares to deliver ordinary shares to participants in Hansa's incentive programs and to cover social contributions resulting from these programs.

As of June 28, 2024, Hansa Biopharma's total number of registered shares stands at 67,814,241, all of which are ordinary shares. Correspondingly, the number of votes also totals 67,814,241, and the registered share capital amounts to SEK 67,814,241.

Positive

• Increased share capital by SEK 2,305,260.
• Converted 2,362,445 class C shares to ordinary shares for incentive programs.

Negative

• Potential dilution of existing shareholders' equity due to the increase of new shares.

LUND, Sweden, June 28, 2024 /PRNewswire/ -- Hansa Biopharma AB, ("Hansa Biopharma" or the "Company") (NASDAQ: HNSA) (STOCKHOLM: HNSA) today announced that Hansa's registered share capital and number of shares and votes have increased through (i) the issue of 2,305,260 new ordinary shares resolved on 12 April 2024 and registered with the Swedish Companies Registration Office during June 2024, whereby the number of votes increased with 2,305,260 and the share capital increased with SEK 2,305,260, and (ii) conversion of all 2,362,445 issued class C shares in Hansa to a total of 2,362,445 ordinary shares, in order to deliver ordinary shares to participants in Hansa's outstanding incentive programs and to secure social contributions arising as a result of the incentive programs.

As of today, the total number of registered shares of Hansa amounts to 67,814,241, of which all are ordinary shares. As of today, the number of votes in Hansa amounts to 67,814,241, and the registered share capital amounts to SEK 67,814,241.

This disclosure contains information that Hansa Biopharma AB is obliged to make public pursuant to the Swedish Financial Instruments Trading Act (1991:980). The information was submitted for publication, through the agency of the contact persons below, on June 28, 2024 at 07:00 CEST.

Contacts for more information:
Evan Ballantyne, Chief Financial Officer
IR@hansabiopharma.com

Stephanie Kenney, VP Global Corporate Affairs
media@hansabiopharma.com

About Hansa Biopharma

Hansa Biopharma is a pioneering commercial-stage biopharmaceutical company on a mission to develop and commercialize innovative, lifesaving and life-altering treatments for patients with rare immunological conditions. Hansa Biopharma has developed a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients. Hansa Biopharma has a rich and expanding research and development program based on the Company's proprietary IgG-cleaving enzyme technology platform, to address serious unmet medical needs in transplantation, autoimmune diseases, gene therapy and cancer. Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at www.hansabiopharma.com and follow us on LinkedIn.

©2024 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/hansa-biopharma-ab/r/hansa-biopharma--increase-in-number-of-shares-and-votes,c4003536

The following files are available for download:

https://mb.cision.com/Main/1219/4003536/2885484.pdf

20240628 - HNSA - Increase in number of shares and votes June 2024_ENG

 

View original content:https://www.prnewswire.com/news-releases/hansa-biopharma-increase-in-number-of-shares-and-votes-302185481.html

SOURCE Hansa Biopharma AB

FAQ

How many new shares did Hansa Biopharma issue?

Hansa Biopharma issued 2,305,260 new ordinary shares.

What is the current total number of registered shares for Hansa Biopharma?

The total number of registered shares for Hansa Biopharma is 67,814,241.

How many votes are there in Hansa Biopharma as of June 28, 2024?

As of June 28, 2024, the number of votes in Hansa Biopharma is 67,814,241.

Why did Hansa Biopharma convert class C shares to ordinary shares?

Hansa Biopharma converted class C shares to ordinary shares to deliver ordinary shares to participants in their incentive programs and to secure social contributions arising from these programs.

By how much did Hansa Biopharma's share capital increase?

Hansa Biopharma's share capital increased by SEK 2,305,260.